Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

[Tubulointerstitial changes in some hematological disorders]

H Morita1, T Shinzato, K Maeda

  • 1Department of Internal Medicine, Branch Hospital of Nagoya University, School of Medicine.

Nihon Rinsho. Japanese Journal of Clinical Medicine
|August 1, 1995
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Inhibition of aldosterone turn-off phenomenon following chronic adrenocorticotropin treatment with in vivo administration of antiglucocorticoid and antioxidants in rats.

European journal of endocrinology·1995
Same author

Relationship between susceptibility to apoptosis and Fas expression in peripheral blood T cells from uremic patients: a possible mechanism for lymphopenia in chronic renal failure.

Biochemical and biophysical research communications·1995
Same author

[Clinicopathological evaluation of etoposide or estramustine phosphate in castrated patients with advanced prostatic cancer].

Nihon Hinyokika Gakkai zasshi. The japanese journal of urology·1995
Same author

Two regions of GLUT 2 glucose transporter protein are responsible for its distinctive affinity for glucose.

Endocrinology·1995
Same author

Eucalyptone from Eucalyptus globulus.

Phytochemistry·1995
Same author

Studies on cognitive enhancing agents. II. Antiamnestic and antihypoxic activities of 1-aryl-2-(2-aminoethoxy)ethanols.

Chemical & pharmaceutical bulletin·1995
Same journal

[Development of novel therapeutics for multiple myeloma and improvement of drug lag].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Clinical pharmacy services to patients of immunomodulatory drugs].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Therapeutic drug monitoring of the new anti-myeloma drugs in the treatment of multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Prognostic value of minimal residual disease assessment using next-generation sequencing in multiple myeloma].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[The evaluation of minimal residual disease in multiple myeloma by an allele-specific oligonucleotide real-time PCR].

Nihon rinsho. Japanese journal of clinical medicine·2019
Same journal

[Evaluation of minimal residual disease in myeloma by multiparametric flow cytometry].

Nihon rinsho. Japanese journal of clinical medicine·2019
See all related articles

Kidney tubulointerstitial changes are linked to paraprotein disorders like myeloma kidney and chemotherapy for leukemia/lymphoma. Abnormal macromolecule accumulation and drug toxicity are key causes.

Area of Science:

  • Nephrology
  • Hematology
  • Oncology

Context:

  • Tubulointerstitial diseases represent a significant kidney pathology.
  • Paraproteinemias and hematological malignancies are associated with renal complications.
  • Chemotherapy for hematological cancers can induce kidney damage.

Purpose:

  • To elucidate the mechanisms of tubulointerstitial changes in paraproteinuric disorders.
  • To describe the impact of leukemia and lymphoma management on kidney function.
  • To review the drugs causing tubulitis and interstitial fibrosis.

Summary:

  • Paraprotein accumulation, as seen in multiple myeloma (light chain cast nephropathy), AL amyloidosis, and light chain deposition disease, can provoke tubulointerstitial damage.
  • While leukemia and lymphoma themselves are not primary causes of tubulointerstitial disorders, their treatment, particularly chemotherapy, frequently leads to such complications.

Related Experiment Videos

  • Specific chemotherapeutic agents are implicated in causing tubulitis and interstitial fibrosis, highlighting the nephrotoxic potential of cancer therapies.

    • Impact:

    • Provides a comprehensive overview of kidney tubulointerstitial pathologies in the context of hematological disorders.
    • Enhances understanding of drug-induced nephrotoxicity in cancer patients.
    • Informs clinical management strategies for preventing and treating kidney complications in patients with paraproteinemias and hematological malignancies.